Document:

EX-4.1

 Exhibit 4.1 

ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

May 30, 2019 

 SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of May 30, 2019,
by and between (i) Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), (ii) each of the investors listed on Schedule A hereto, each of whom is referred to in this Agreement as an
“Investor,” and (iii) solely for purposes of Sections 5 and 6 hereof, each of Chad Robins and Harlan Robins and their permitted transferees (the “Key Holders”). 

RECITALS 

A.    The Company and certain Investors are party to the Sixth Amended and Restated Investors’ Rights Agreement,
dated as of December 11, 2017 (the “Prior IRA”). 
 B.     This Agreement amends and restates in
its entirety the Prior IRA. 
 NOW, THEREFORE, in consideration of the mutual covenants of the parties herein and other good and valuable
consideration, the parties agree as follows: 
 AGREEMENT 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who or which, directly
or indirectly, controls, is controlled by, or is under common control with such specified Person, including without limitation any partner, officer, director, manager or employee of such Person and any venture capital fund now or hereafter existing
that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such Person. 

1.2    “Amended Articles” means the Company’s Amended and Restated Articles of Incorporation as
filed on or about the date of this Seventh Amended and Restated Investors’ Rights Agreement. 

1.3    “Common Stock” means shares of the Company’s common stock, no par value per share. 

1.4    “Damages” means any loss, claim, damage, or liability (joint or several) to which a party hereto
may become subject, insofar as such loss, claim, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration
statement of the Company, including any preliminary prospectus or final prospectus contained therein, any amendments or supplements thereto or any documents incorporated by reference therein; (ii) an omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by any other party hereto of the Securities Act, the Exchange Act, any state
securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

  
 1 

 1.5    “Exchange Act” means the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6    “Excluded
Registration” means a registration relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan or to an SEC Rule 145 transaction; a registration on any form that
does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered. 
 1.7    “GAAP” means
generally accepted accounting principles in the United States. 
 1.8    “Holder” means any holder of
Registrable Securities who is a party to this Agreement. 
 1.9    “Immediate Family Member” means a
child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.10    “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.11    “IPO” means the Company’s first underwritten public offering of
its Common Stock for cash pursuant to an effective registration statement (other than on Form S-4, S-8 or a comparable form) under the Securities Act. 

1.12    “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 550,000 shares of Registrable Securities (as adjusted for any stock dividends, splits, combinations, recapitalizations, reclassifications or the like effected after the date hereof with respect to such securities). 

1.13    “Material Adverse Change” means (i) any general suspension of trading in, or limitation on
prices for, securities on any national securities exchange or in the over-the-counter market in the United States; (ii) the declaration of a banking moratorium or
any suspension of payments in respect of banks in the United States; (iii) a material outbreak or escalation of armed hostilities or other international or national calamity involving the United States or the declaration by the United States of
a national emergency or war or a change in national or international financial, political or economic conditions; and (iv) any event, change, circumstance or effect that is or is reasonably likely to be materially adverse to the business,
properties, assets, liabilities, condition (financial or otherwise), operations, results of operations or prospects of the Company. 

  
 2 

 1.14    “New Securities” means, collectively, equity
securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable
for such equity securities. 
 1.15    “Person” means any individual, corporation, partnership, trust,
limited liability company, association or other entity. 
 1.16    “Preferred Stock” means shares of
the Series A Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock, the Series E-1 Preferred Stock, the Series F Preferred
Stock and the Series F-1 Preferred Stock. 

1.17    “Register,” “registered,” and “registration” refer to a
registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

1.18    “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of
the Preferred Stock, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the rights under Section 2 hereof are not assigned or
any shares for which registration rights have terminated pursuant to Section 2.15 of this Agreement. 

1.19    “Registrable Securities then outstanding” means the number of shares determined by adding the
Common Stock outstanding and the Common Stock issuable pursuant to then exercisable or convertible securities that are Registrable Securities. 

1.20    “Restricted Securities” means the securities of the Company required to bear the legend set forth
in Section 2.14(b) hereof. 
 1.21    “SEC” means the U.S. Securities and
Exchange Commission. 
 1.22    “SEC Rule 144” means Rule 144 promulgated by the SEC under the
Securities Act. 
 1.23    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities
Act. 
 1.24    “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder. 
 1.25    “Selling Expenses” means all underwriting discounts,
selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except as provided in Section 2.7. 

  
 3 

 1.26    “Series A Preferred Stock”
means shares of the Company’s Series A Preferred Stock. 
 1.27    “Series B
Preferred Stock” means shares of the Company’s Series B Preferred Stock. 

1.28    “Series C Preferred Stock” means shares of the Company’s Series C
Preferred Stock. 
 1.29    “Series D Preferred Stock” means shares of the
Company’s Series D Preferred Stock. 
 1.30    “Series E Preferred Stock”
means shares of the Company’s Series E Preferred Stock. 
 1.31    “Series E-1 Preferred Stock” means shares of the Company’s Series E-1 Preferred Stock. 

1.32    “Series F Preferred Stock” means shares of the Company’s Series F
Preferred Stock. 
 1.33    “Series F-1
Preferred Stock” means shares of the Company’s Series F-1 Preferred Stock. 

1.34    “Shelf Registration Statement” means a registration statement of the Company filed with the SEC
on either (i) Form S-3 (or any successor form or other appropriate form under the Securities Act) or (ii) if the Company is not permitted to file a registration statement on Form S-3, an evergreen registration statement on Form S-1 (or any successor form or other appropriate form under the Securities Act), in each case for an offering to be made on a
continuous or delayed basis pursuant to Rule 415 under the Securities Act (or any similar rule that may be adopted by the SEC) covering all or any portion of the Registrable Securities, as applicable. To the extent that the Company is a
“well-known seasoned issuer” (as such term is defined in Rule 405 (or any successor or similar rule) of the Securities Act), a “Shelf Registration Statement” shall be deemed to refer to an “automatic shelf registration
statement,” as such term is defined in Rule 405 (or any successor or similar rule) of the Securities Act. 

1.35    “Viking” means, Viking Global Investors LP, or any of its Affiliates or successors. 

2.    Registration Rights. The Company covenants and agrees as follows: 

2.1    Demand Registration. 

(a)    If at any time after the expiration of six months following the closing date of the IPO, the Company receives a
request from (i) Holders of thirty percent (30%) of the Registrable Securities then outstanding or (ii) Viking, so long as it remains a Major Investor, that the Company effect a registration with respect to the Registrable Securities then
outstanding having an anticipated aggregate offering price to the public of not less than $5 million, then the Company shall use its best efforts to: (i) within ten (10) days after the date such request is given, give notice thereof
(the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) file a registration statement on Form S-1 or any similar long-form registration statement (a
“Long-Form Registration Statement”) or, if available, a registration statement on Form S-3 or any similar short-form registration statement (a “Short-Form Registration
Statement”), other than a Shelf Registration Statement, as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, in the case of a Long-Form Registration Statement
or within thirty (30) days after the date such request is given by the Initiating Holders, in the case of a Short-Form Registration Statement, in each case covering all Registrable Securities that the Initiating Holders requested to be
registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is
given, and in each case, subject to the limitations of Section 2.1(b). 

  
 4 

 (b)    If the Company qualifies to use a Short-Form Registration
Statement after the date that a Long-Form Registration Statement is filed or declared effective, the Company may convert such Long-Form Registration Statement into a Short-Form Registration Statement. 

(c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant
to this Section 2.1 a certificate signed by the Company’s Chairman of the Board stating that in the good faith judgment of the Company’s Board of Directors, after consultation with outside counsel to the Company,
it would be materially detrimental to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, then
the Company shall have the right, upon giving prompt written notice of such action to the Holders, to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled
correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right or the right under Section 2.3(b) (A)
more than once in any twelve (12)-month period; or (B) for an aggregate period exceeding ninety (90) days in any twelve (12)-month period. 

(d)    The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this
Section 2.1 (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is sixty (60) days after the effective date of, a registration
statement pertaining to an underwritten public offering of the Company’s securities, and (ii) after the Company has effected five (5) registrations pursuant to Section 2.1 if the Initiating Holders for at least two
(2) of such registrations shall have been Viking or its Affiliates. A registration shall not be counted as “effected” for purposes of this Section 2.1 until such time as the applicable registration statement
has been declared effective by the SEC and remains effective for not less than one hundred and twenty (120) days without any occurrence of a Material Adverse Change (or such shorter period as shall terminate when all Registrable Securities
covered thereunder have been sold), unless the Initiating Holders withdraw their request for such registration, elect not to reimburse the Company for the registration expenses therefor, and forfeit their right to one demand registration statement
pursuant to Section 2.7, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1. 

  
 5 

 2.2    Company Registration. If the Company proposes to register
(including, for this purpose, a registration effected by the Company for shareholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash
(other than an Excluded Registration), the Company shall, at such time, promptly (but in no event less than forty five (45) days prior to the proposed date of filing of such registration statement), give each Holder notice of such registration.
Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.4, cause to be registered all of the Registrable
Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date
of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses of such withdrawn registration shall be borne by the Company in accordance with
Section 2.7. 
 2.3    Shelf Registration. If at any time after the expiration
of six months following the closing date of the IPO, the Company receives a request from (i) Holders of at least twenty percent (20%) of the Registrable Securities then outstanding, (ii) Viking, so long as it remains a Major Investor, that
the Company file with the SEC a Shelf Registration Statement with respect to all or a part of the Registrable Securities owned by such Initiating Holders, then the Company shall: 

(a) within ten (10) days after the date such request is given, give notice of the proposed registration to all Holders other than the
Initiating Holders (the “Shelf Notice”); and 
 (b)    as soon as practicable, use its commercially
reasonable efforts to effect such registration as would permit or facilitate the sale and distribution from time to time of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such request, together with
all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a request given to the Company within fifteen (15) days after the Shelf Notice is given; 

(c)    provided, however, that the Company shall not be obligated to file a Shelf Registration Statement
pursuant to this Section 2.3 (i) if the Holders, together with the holders of any other securities of the Company entitled to and requesting inclusion in such registration, propose to sell Registrable Securities and
such other securities (if any) at an aggregate offering price to the public (net of Selling Expenses) of less than $2 million; or (ii) if the Company furnishes to the Holders a certificate signed by the Chairman of the Board of the Company
stating that in the good-faith judgment of the Board of Directors of the Company, after consultation with outside counsel to the Company, it would be materially detrimental to the Company and its shareholders for such Shelf Registration Statement to
be effected at such time, in which event the Company shall have the right, upon giving prompt written notice of such action to the Holders, to defer the filing of the Shelf Registration Statement for a period of not more than sixty (60) days
after receipt of the request of the Initiating Holders under this Section 2.3; provided, however, that the Company shall not invoke this right or the right under Section 2.1(c) (A) more than
once in any twelve (12) month period; (B) for an aggregate period exceed ninety (90) days in any twelve (12) month period; or (C) during the period ending sixty (60) days after the effective date of a registration made
under Section 2.2 hereof. Registrations effected pursuant to this Section 2.3 shall not be counted as demands for registration or registrations effected pursuant to
Section 2.1. 

  
 6 

 2.4    An offering or sale of Registrable Securities pursuant to a Shelf
Registration Statement (each, a “Shelf Take-Down”) may be initiated at any time by one or more Major Investors; provided, that the minimum market value of Registrable Securities that such Holder(s) (the “Initiating Shelf
Take-Down Holders”) propose to sell in such offering must be, on the date such Holder submits its written request to the Company, equal to at least (A) $1 million or (B) such lower amount approved by the Board; provided that, if
the Board approves any such lower amount, it shall be applicable to all Holders. The Initiating Shelf Take-Down Holders shall not be required to permit the offer and sale of Registrable Securities by other Shelf Holders in connection with any such
Shelf Take-Down initiated by the Initiating Shelf Take-Down Holders and no Shelf Holder other than the Initiating Shelf Take-Down Holder(s) shall be entitled to offer or sell any Registrable Securities pursuant to such Shelf Take-Down. 

2.5    Underwriting Requirements. 

(a)    Any registration pursuant to Section 2.1 shall be firmly underwritten. If, pursuant to
Section 2.3, the Initiating Holders intend to distribute the Registrable Securities covered by a Shelf Take-Down by means of an underwriting, the Initiating Holders shall so advise the Company as a part of their
request made pursuant to Section 2.3, and the Company shall amend or supplement the Shelf Registration Statement for such purpose as soon as practicable. Any underwriter of an offering required to be registered under
Section 2.1 or 2.3 shall be selected by the Company, shall be of nationally recognized standing, and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, any right of any
Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to
the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.5(e)) enter into an underwriting agreement in customary
form with the managing underwriter(s) selected for such underwriting; provided that the aggregate amount of the liability of any Holder thereunder shall not exceed such Holder’s gross proceeds from such underwriting (less Selling Expenses).
Notwithstanding any other provision of this Section 2.4, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten,
then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among all
Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities of the Company owned by each Holder; provided, however, that the number of
Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

  
 7 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the customary terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. 

(c)    If the total number of securities, including Registrable Securities, to be included in such offering exceeds the
number of securities to be sold that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities,
including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to
be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated (i) in the case of the IPO, (A) first to the Company, (B) second, and only if all of the securities
referred to in clause (A) have been included, to Viking and its Affiliates with respect to any Registrable Securities owned by them (as allocated by Viking) and (C) third, and only if all of the securities referred to in clause
(B) have been included, apportioned pro rata among the other selling Holders based on the number of Registrable Securities held by all such selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders
and (ii) in the case of any other offering, (A) first to the Company and (B) second, and only if all of the securities referred to in clause (A) have been included, pro rata among the other selling Holders based on the number of
Registrable Securities held by all such selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by any Holder to be
included in such underwriting shall not be reduced unless all securities held by Persons other than the Company and the Holders are first entirely excluded from the underwriting. For purposes of the provision in this
Section 2.4(b) concerning apportionment, for any selling shareholder that is a Holder and a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, shareholders, and
Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling
Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this
sentence. 
 2.6    Obligations of the Company. Whenever required under this Section 2
to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be
extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on a Shelf Registration Statement that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to three (3) years, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

  
 8 

 (b)    prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be (x) reasonably request by any Major Investor or (y) necessary to comply with the Securities Act in order to enable the
disposition of all securities covered by such registration statement; 
 (c)    furnish to the selling Holders, without
charge, such numbers of copies of a prospectus, including a preliminary prospectus, and any amendment or supplement thereto as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate
their disposition of their Registrable Securities; 
 (d)    use its commercially reasonable efforts to register and
qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided, that
the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required
by the Securities Act; 
 (e)    in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering and take all such other actions as any Major Investor or the managing underwriter reasonably requests in order to expedite or
facilitate the registration and disposition of the Registrable Securities; 
 (f)    use its commercially reasonable
efforts to cause all such Registrable Securities covered by such registration statement to be listed or quoted on a national securities exchange or trading or quotation system and each securities exchange and trading or quotation system (if any) on
which similar securities issued by the Company are then listed; 
 (g)    provide a transfer agent and registrar for all
Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with any such
registration statement; 

  
 9 

 (i)    obtain for delivery to the underwriter or underwriters, if any,
with copies to the selling Holders, an opinion or opinions from counsel for the Company dated the effective date of the registration statement, or in the event of an underwritten offering, the date of the closing under the underwriting agreement, in
customary form, scope and substances, which opinions shall be reasonably satisfactory to such Holder or underwriters and their respective counsel; 

(j)    in the case of an underwritten offering, obtain for delivery to the Company and the managing underwriter or
underwriters, with copies to the selling Holders, a cold comfort letter from the Company’s independent accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the managing underwriter
or underwriters may reasonably request, dated the date of execution of the underwriting agreement and brought down to the closing under the underwriting agreement; 

(k)    in the case of an underwritten offering, cause the senior executive officers of the Company to participate in the
customary “road show” presentations that may be reasonably requested by the managing underwriter or underwriters in any such offering and otherwise to facilitate, cooperate with and participate in each proposed offering contemplated herein
and customary selling efforts related thereto; 
 (l)    notify each selling Holder, promptly after the Company receives
notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; 

(m)    after such registration statement becomes effective, notify each selling Holder of any written comments by the SEC
or request by the SEC that the Company amend or supplement such registration statement or prospectus or of the issuance by the SEC of any stop order suspending the effectiveness of such registration statement; 

(n)    notify each selling Holder and any managing underwriter if it becomes aware of the happening of any event as a
result of which the registration statement contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading; and 

(o)    cooperate with each selling Holder and any managing underwriter, if any, to facilitate the timely preparation and
delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends. 

2.7    Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the
intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  
 10 

 2.8    Expenses of Registration. All expenses (other than Selling
Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements
of counsel for the Company; and the reasonable fees and disbursements, not to exceed $100,000 or such greater amount as agreed upon in the applicable underwriting agreement, of one counsel for the selling Holders, which counsel shall be selected by
the Holder that, together with its affiliates, is offering to sell the greatest number of Registrable Securities in such offering, shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay
for any expenses of any registration proceeding begun pursuant to Section 2.1 or Section 2.3 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the withdrawal is made
following the occurrence of a Material Adverse Change. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the
number of Registrable Securities registered on their behalf. 
 2.9    Indemnification. If any Registrable
Securities are included in a registration statement under this Section 2: 
 (a)    To the
extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as
defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, and each of their respective Affiliates, officers, trustees,
directors, shareholders, employees and agents, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating any matter or defending any proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.9(a) shall
not apply to amounts paid in settlement of any such investigation or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed, nor shall the Company be
liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b)    To the extent permitted by
law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter
or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling
Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating any
investigation or defending any proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.9(b) shall not apply to
amounts paid in settlement of any such investigation or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld, conditioned or delayed; and provided, further, that
in no event shall any indemnity under this Section 2.9(b) exceed the proceeds from the offering (net of any Selling Expenses) received by such Holder, except in the case of fraud or willful misconduct by such Holder. 

  
 11 

 (c)    Promptly after receipt by an indemnified party under this
Section 2.9 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 2.9, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the
indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.9, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.9. 
 (d)    The
foregoing indemnity agreements of the Company and the selling Holders are subject to the condition that, insofar as they relate to any Damages arising from any untrue statement or alleged untrue statement of a material fact contained in, or omission
or alleged omission of a material fact from, a preliminary prospectus (or necessary to make the statements therein not misleading) that has been corrected in the form of prospectus included in the registration statement at the time it becomes
effective, or any amendment or supplement thereto filed with the SEC pursuant to Rule 424(b) under the Securities Act (the “Final Prospectus”), such indemnity agreement shall not inure to the benefit of any Person if a copy of
the Final Prospectus was furnished to the indemnified party and such indemnified party failed to deliver, at or before the confirmation of the sale of the shares registered in such offering, a copy of the Final Prospectus to the Person asserting the
loss, liability, claim, or damage in any case in which such delivery was required by the Securities Act. 

  
 12 

 (e)    To provide for just and equitable contribution to joint liability
under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.9 but it is judicially determined (by the
entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.9 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.9, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of the each of indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold
by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not
guilty of such fraudulent misrepresentation; and provided, further, that in no event shall a Holder’s liability pursuant to this Section 2.9(e), when combined with the amounts paid or payable by such
Holder pursuant to Section 2.9(b), exceed the proceeds from the offering (net of any Selling Expenses) received by such Holder, except in the case of willful misconduct or fraud by such Holder. 

(f)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(g)    Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public
offering, the obligations of the Company and Holders under this Section 2.9 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.10    Reports Under Exchange Act. With a view to
making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a Shelf Registration
Statement, the Company shall: 
 (a)    make and keep public information available, as those terms are understood and
defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

  
 13 

 (b)    use commercially reasonable efforts to file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to a Shelf Registration Statement (at any time after the
Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to such Shelf
Registration Statement (at any time after the Company so qualifies to use such form). 
 2.11    Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may
include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) to demand registration of any securities
held by such holder or prospective holder; provided, that this limitation shall not apply to any Additional Investor who becomes a party to this Agreement in accordance with Section 6.10. 

2.12    “Market Stand-off” Agreement. Each Holder hereby agrees
that, if requested in writing by the managing underwriter, it will not, without the prior written consent of the managing underwriter, during the 180-day period following the effective date of the registration
statement relating to the IPO or during the 90-day period following the effective date of a registration statement relating to a subsequent public offering (or, in either case, such other period, not to exceed
thirty-four (34) additional days, as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (A) the publication or other distribution of research reports and (B) analyst recommendations and
opinions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto) effect any public sale or distribution of any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock; provided, that such restrictions shall not apply to (i) securities acquired in the IPO or a subsequent public offering or in the secondary market following the IPO or a subsequent public offering,
(ii) transfers to Affiliates but only if such Affiliates agree to be bound by the restrictions herein and (iii) in respect of any offering other than the IPO, transfers pursuant to customary 10b-5(1)
plans in amounts that would permitted to be sold under SEC Rule 144 under the Securities Act inclusive of the volume limitations under SEC Rule 144. The foregoing provisions of this Section 2.12 shall not apply to the sale
of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors, and shareholders individually owning more than one percent (1%) of the Company’s outstanding Common
Stock are subject to the same restrictions. The underwriters in connection with the IPO are intended third-party beneficiaries of this Section 2.12 and shall have the right, power,
and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the IPO that are consistent with this
Section 2.12 or that are necessary to give further effect thereto. 

  
 14 

 2.13    Assignment of Registration Rights. The rights to cause
the Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all related obligations) by a Holder to a transferee of such Registrable Securities that (i) is an Affiliate,
partner, member, limited partner, retired partner, retired member, or shareholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate
Family Members; or (iii) in such transfer, acquires at least 10% of such Holder’s shares of Registrable Securities; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with
written notice of the name and address of such transferee and the Registrable Securities with respect to which such registration rights are being transferred; (y) such transferee agrees in writing to be bound by and subject to the terms and
conditions of this Agreement, including the provisions of Section 2.12. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an
Affiliate, limited partner, retired partner, member, retired member, or shareholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such
Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided, further, that all transferees who would not qualify individually for assignment of registration rights shall have a
single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Section 2. 

2.14    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause
any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b)    Each certificate representing (i) the Preferred Stock, (ii) the Registrable Securities, and
(iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by
the provisions of Section 2.14(c)) be stamped or otherwise imprinted with a legend in the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN 

ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED 

UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE 

SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH 

REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION 

AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

  
 15 

 THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE 

TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN 

AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A 

COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to
implement the restrictions on transfer set forth in this Section 2.14. 
 (c)    The holder of
each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities,
unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such
notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of
legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a
“no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect
thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act,
whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal
opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder; provided that each transferee
agrees in writing to be subject to the terms of this Section 2.14(c). Each certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC
Rule 144, the appropriate restrictive legend set forth in Section 2.14(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend
is not required in order to establish compliance with any provisions of the Securities Act. 
 2.15    Termination of
Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1, Section 2.2, or
Section 2.3 shall terminate upon the earlier of: 
 (a)    five (5) years after the IPO;
or 

  
 16 

 (b)    when such Holder is legally permitted to sell all of such
Holder’s Registrable Securities without registration under the Securities Act during a 90-day period or less, pursuant to SEC Rule 144, or any other applicable exemption from registration. 

Notwithstanding the foregoing, the right of any Major Investor to request registration or inclusion of Registrable Securities in any
registration pursuant to Section 2.1, Section 2.2, or Section 2.3 shall not terminate until such time as such Major Investor holds no Registrable Securities. 

3.    Information Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided, that
such Major Investor is an institutional financial investor, individual, trust or entity that is not otherwise a strategic investor: 

(a)    as soon as practicable, but in any event within one hundred eighty (180) days after the end of each fiscal
year of the Company, its audited financial statements as of the end of and for such fiscal year (including a balance sheet, income statement and statement of cash flows), all prepared in accordance with GAAP (except that such financial statements
may not contain all notes thereto that may be required in accordance with GAAP); 
 (b)    as soon as practicable, but
in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company its unaudited financial statements as of the end of and for such
fiscal quarter (including a balance sheet, income statement and statement of cash flows), all prepared in accordance with GAAP (except that the financial report may (i) be subject to normal year-end audit
adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 If, for any period, the Company has any subsidiary
whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all
such consolidated subsidiaries.     
 3.2    Inspection. The Company shall permit each Major
Investor, at such Major Investor’s expense, to visit and inspect the properties of the Company, including its corporate and financial records, and to discuss its business and finances with officers of the Company during normal business hours
upon reasonable advance notice; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably considers to be a trade secret or
confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Termination of Information Rights. The covenants set forth in Section 3.1 shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of section 12(g) or 15(d) of the Exchange Act, or
(iii) upon a Corporate Event (as defined in the Amended Articles), whichever event occurs first. The covenants set forth in Section 3.2 shall terminate and be of no further force or effect upon a Corporate Event. 

  
 17 

 3.4    Confidentiality. Each Investor agrees that such Investor
will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of
the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by
such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a
breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if the Board of Directors reasonably
determines in advance of such disclosure that such prospective purchaser is not a competitor of the Company and such prospective purchaser agrees to be bound by the provisions of this Section 3.4; (iii) to any
Affiliate, partner, member, shareholder, wholly owned subsidiary, or potential partner, member or shareholder of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is
confidential and directs such Person to maintain the confidentiality of such information, and provided further that such Person is not a competitor of the Company, as determined by the Board of Directors; or (iv) as may otherwise be required by
law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4.    Rights to Future Stock Issuances 

4.1    Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in
such proportions as it deems appropriate, among (i) itself and (ii) its Affiliates; provided that each such Affiliate (x) is not a competitor of the Company, as reasonably determined by the Board of Directors, unless such party’s
purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter into this Agreement and the Sixth Amended and Restated Voting Agreement dated as of December 11, 2017 among the Company, the Investors
and the other parties named therein, as an “Investor” under each such agreement. 
 (a)    The Company shall
give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any,
upon which it proposes to offer such New Securities. 
 (b)    By notification to the Company within twenty
(20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that
the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable upon conversion of the Preferred Stock then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) (with respect to each Major Investor, such Major Investor’s “Pro Rata Portion”); provided, however, that the
portion of New Securities offered to the Major Investors pursuant to this Section 4 may be reduced by up to fifty percent (50%) of each Major Investor’s Pro Rata Portion if the Board of Directors (x) unanimously determines in
good faith that such a reduction is necessary to attract strategically required investment in the Company and (y) notifies the Major Investors of such determination and each Major Investors’ cut-back
portion of the New Securities in the Offer Notice. At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully
Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company,
elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal
to the proportion that the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such Fully Exercising Investor bears to the total number of shares of Common Stock then issuable upon conversion of the
Preferred Stock then held by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the
Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 
  

  
 18 

 (c)    If all New Securities referred to in the Offer Notice are not
elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Major Investors in accordance with this Subsection 4.1. 
 (d)    The right of first offer
in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Amended Articles); and (ii) shares of Common Stock issued in the IPO. 

4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or
effect (i) immediately before the consummation of the QPO (as defined in the Amended Articles) or (ii) upon a Corporate Event (as defined in the Amended Articles), whichever event occurs first.  

5.    Right of Co-Sale. 

5.1    Definitions. For purposes of this Section 5: 

  
 19 

 (a)    “Proposed Key Holder Transfer” means any
assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance, disposition of or any other like transfer or encumbering of any Transfer Stock (or any interest therein) proposed by any of the Key Holders. 

(b)    “Proposed Transfer Notice” means written notice from a Key Holder setting forth the terms and
conditions of a Proposed Key Holder Transfer. 
 (c)    “Prospective Transferee” means any person to
whom a Key Holder proposes to make a Proposed Key Holder Transfer. 
 (d)    “Right of Co-Sale” means the right, but not an obligation, of an Investor to participate in a Proposed Key Holder Transfer on the terms and conditions specified in the Proposed Transfer Notice. 

(e)    “Transfer Stock” means shares of Common Stock or Preferred Stock owned by a Key Holder, or issued
to a Key Holder after the date hereof (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like). 

5.2    Right of Co-Sale. 

(a)    Grant. Subject to the terms of Sections 5.4 and 5.5 below, each Key Holder hereby
unconditionally and irrevocably grants to each Major Investor a Right of Co-Sale to participate on a pro rata basis in any Proposed Key Holder Transfer. 

(b)    Notice. Each Key Holder proposing to make a Proposed Key Holder Transfer must deliver a Proposed Transfer
Notice to the Company and each Major Investor not later than thirty (30) days prior to the consummation of such Proposed Key Holder Transfer. Such Proposed Transfer Notice shall contain the material terms and conditions (including price and
form of consideration) of the Proposed Key Holder Transfer, the identity of the Prospective Transferee and the intended date of the Proposed Key Holder Transfer. 

(c)    Exercise of Right. Each Major Investor may elect to exercise its Right of
Co-Sale and participate on a pro rata basis in the Proposed Key Holder Transfer as set forth in Subsection 2.2(d) below and, subject to Subsection 2.2(e), otherwise on the same terms and
conditions specified in the Proposed Transfer Notice. Each Major Investor who desires to exercise its Right of Co-Sale (each, a “Participating Major Investor”) must give the selling Key Holder
written notice to that effect within fifteen (15) days after the deadline for delivery of the Proposed Transfer Notice described above, and upon giving such notice such Participating Major Investor shall be deemed to have effectively exercised
the Right of Co-Sale. 
 (d)    Shares Includable. Each Participating
Major Investor may include in the Proposed Key Holder Transfer all or any part of such Participating Major Investor’s shares of Common Stock issued or issuable upon conversion of Preferred Stock equal to the product obtained by multiplying
(i) the aggregate number of shares of Common Stock issued or issuable upon conversion of Transfer Stock subject to the Proposed Key Holder Transfer by (ii) a fraction, the numerator of which is the number of shares of Common Stock issued
or issuable upon conversion of Preferred Stock then owned by such Participating Major Investor immediately before consummation of the Proposed Key Holder and the denominator of which is the total number of shares of Common Stock issued or issuable
upon conversion of Preferred Stock then owned, in the aggregate, by all Participating Major Investors immediately prior to the consummation of the Proposed Key Holder Transfer, plus the number of shares of Common Stock issued or issuable upon
conversion of Transfer Stock held by the Key Holders. To the extent one (1) or more of the Participating Major Investors exercise such right of participation in accordance with the terms and conditions set forth herein, the number of shares of
Transfer Stock that the selling Key Holder may sell in the Proposed Key Holder Transfer shall be correspondingly reduced. 

  
 20 

 (e)    Purchase and Sale Agreement. The Participating Major
Investors and the selling Key Holder agree that the terms and conditions of any Proposed Key Holder Transfer in accordance with Subsection 5.2 will be memorialized in, and governed by, a written purchase and sale agreement with the
Prospective Transferee (the “Purchase and Sale Agreement”) with customary terms and provisions for such a transaction, and the Participating Major Investors and the selling Key Holder further covenant and agree to enter into such
Purchase and Sale Agreement as a condition precedent to any sale or other transfer in accordance with this Subsection 5.2; provided, that (1) any liability under such Purchase and Sale Agreement shall be several, and not
joint, and (2) no Participating Major Investor shall be required to enter into an “non-competition” or similar restriction in connection with any such Purchase and Sale Agreement. 

(f)    Allocation of Consideration. The aggregate consideration payable to the Participating Major Investors and
the selling Key Holder shall be allocated based on the number of shares of Common Stock sold to the Prospective Transferee by each Participating Major Investor and the selling Key Holder as provided in Subsection 5.2(d), provided that
if a Major Investor or Participating Major Investor wishes to sell Preferred Stock, the price set forth in the Proposed Transfer Notice shall be appropriately adjusted based on the conversion ratio of the Preferred Stock into Common Stock. 

(g)    Purchase by Selling Key Holder; Deliveries. Notwithstanding Subsection 5.2(e) above, if any
Prospective Transferee refuse(s) to purchase securities subject to the Right of Co-Sale from any Participating Major Investor or upon the failure to negotiate in good faith a Purchase and Sale Agreement
reasonably satisfactory to the Participating Major Investors, no Key Holder may sell any Transfer Stock to such Prospective Transferee unless and until, simultaneously with such sale, such Key Holder purchases all securities subject to the Right of Co-Sale from such Participating Major Investor on the same terms and conditions (including the proposed purchase price) as set forth in the Proposed Transfer Notice and as provided in Subsection 5.2(f). In
connection with such purchase by the selling Key Holder, such Participating Major Investor shall deliver to the selling Key Holder a stock certificate or certificates, properly endorsed for transfer, representing the Common Stock being purchased by
the selling Key Holder. Each such stock certificate delivered to the selling Key Holder will be transferred to the Prospective Transferee against payment therefor in consummation of the sale of the Transfer Stock pursuant to the terms and conditions
specified in the Proposed Transfer Notice, and the selling Key Holder shall concurrently therewith remit or direct payment to each such Participating Major Investor the portion of the aggregate consideration to which each such Participating Major
Investor is entitled by reason of its participation in such sale as provided in this Subsection 5.2(g). 

  
 21 

 (h)    Additional Compliance. If any Proposed Key Holder Transfer
is not consummated within forty-five (45) days after receipt of the Proposed Transfer Notice by the Company, the Key Holders proposing the Proposed Key Holder Transfer may not sell any Transfer Stock unless they first comply in full with each
provision of this Section 5. The exercise or election not to exercise any right by any Major Investor hereunder shall not adversely affect its right to participate in any other sales of Transfer Stock subject to this
Subsection 5.2. 
 5.3    Effect of Failure to Comply. 

(a)    Transfer Void; Equitable Relief. Any Proposed Key Holder Transfer not made in compliance with the
requirements of this Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of
this Agreement would result in substantial harm to the other parties hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that any
non-breaching party hereto shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance or the
rescission of purchases, sales and other transfers of Transfer Stock not made in strict compliance with this Agreement). 

(b)    Violation of Co-Sale Right. If any Key Holder purports to sell any
Transfer Stock in contravention of the Right of Co-Sale (a “Prohibited Transfer”), each Major Investor who desires to exercise its Right of Co-Sale
under Subsection 5.2 may, in addition to such remedies as may be available by law, in equity or hereunder, require such Key Holder to purchase from such Major Investor the type and number of shares of Common Stock that such Major Investor
would have been entitled to sell to the Prospective Transferee had the Prohibited Transfer been effected in compliance with the terms of Subsection 5.2. The sale will be made on the same terms, including, without limitation, as provided in
Subsection 5.2(f), and subject to the same conditions as would have applied had the Key Holder not made the Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase price) must be made within
ninety (90) days after the Major Investor learns of the Prohibited Transfer, as opposed to the timeframe proscribed in Subsection 5.2. Such Key Holder shall also reimburse each Major Investor for any and all reasonable and
documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Major
Investor’s rights under Subsection 5.2. 
 5.4    Exempted Transfers. Notwithstanding the foregoing
or anything to the contrary herein, the provisions of Subsection 5.2 shall not apply: (a) to a pledge of Transfer Stock that creates a mere security interest in the pledged Transfer Stock, provided that the pledgee thereof agrees in
writing in advance to be bound by and comply with all applicable provisions of this Agreement to the same extent as if it were the Key Holder making such pledge; or (b) upon a transfer of Transfer Stock by such Key Holder made for bona fide
estate planning purposes, either during his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or adopted), sibling, parent or any other direct lineal descendant of such Key Holder (or his or her spouse) (all of
the foregoing collectively referred to as “family members”), or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by such Key Holder or
any such family members; provided that in the case of clause(s) (a) or (b), the Key Holder shall deliver prior written notice to the Major Investors of such pledge, gift or transfer and such shares of Transfer Stock shall at all times remain
subject to the terms and restrictions set forth in this Agreement and such transferee shall, as a condition to such issuance, deliver a counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms
and conditions of this Agreement as a Key Holder (but only with respect to the securities so transferred to the transferee), including the obligations of a Key Holder with respect to Proposed Key Holder Transfers of such Transfer Stock pursuant to
Subsection 5.2. 

  
 22 

 5.5    Exempted Offerings; Termination. Notwithstanding
the foregoing or anything to the contrary herein, the provisions of Section 5 shall not apply to the sale of any Transfer Stock in, and shall terminate and be of no further force or effect immediately prior to (a) the
QPO; or (b) a Corporate Event. 
 5.6    Legend. Each certificate representing shares of Transfer Stock held
by the Key Holders or issued to any permitted transferee in connection with a transfer permitted by Subsection 5.4 hereof shall be endorsed with the following legend: 

THE SALE, PLEDGE, HYPOTHECATION, OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO, AND IN
CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF CERTAIN CO-SALE RIGHTS BY AND BETWEEN THE STOCKHOLDER AND CERTAIN OTHER HOLDERS OF STOCK OF THE CORPORATION. COPIES OF THE AGREEMENT CONTAINING SUCH
RIGHTS MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE CORPORATION. 
 Each Key Holder agrees that the Company may instruct its
transfer agent to impose transfer restrictions on the shares represented by certificates bearing the legend referred to in this Section 5.6 above to enforce the provisions of this Agreement, and the Company agrees to
promptly do so. The legend shall be removed upon termination of this Agreement at the request of the holder. 
 6.    Key Holder Non-Competition and Non-Solicitation. Each Key Holder hereby covenants and agrees with the Company that, until the later of (x) April 3, 2017 and
(y) eighteen (18) months after termination of such Key Holder’s employment with or other services to the Company, such Key Holder will not: (a) directly or indirectly, whether as an owner, director, officer, manager, consultant, agent
or employee, accept employment or engage in activities that directly compete with the business of the Company or with the reasonably anticipated planned product developments of Company as of the date of such Key Holder’s termination of services
to the Company; or (b) solicit, encourage, or cause others to solicit or encourage any employees, customers, clients or suppliers of Company to terminate their employment or customer, client or supplier relationship, as applicable, with the
Company. Each Key Holder acknowledges that due to the nature of the Company’s business, there is no restriction on the geographical scope of such Key Holder’s non-competition obligations to Company.
Each Key Holder further acknowledges that the Company competes on a worldwide basis and that the geographical scope of these limitations is reasonable and necessary for the protection of Company’s trade secrets and other proprietary
information. Each Key Holder further acknowledges that if a court of competent jurisdiction finds this non-competition provision invalid or unenforceable due to unreasonableness in time, geographic scope, or
scope, then such court will interpret and enforce this provision to the maximum extent that such court deems reasonable. The covenants set forth in this Section 6 shall terminate and be of no further force or effect
immediately before the consummation of the QPO. 

  
 23 

 7.    Miscellaneous. 

7.1    Successors and Assigns. Each Investor hereby agrees that it shall not, and may not, assign any of its rights
and obligations hereunder, unless such rights and obligations are assigned by such Investor to any Person to which Registrable Securities are transferred by such Investor pursuant to Section 2.13, and such assignee shall be
deemed an “Investor” for purposes of this Agreement; provided that such assignment of rights shall be contingent upon the assignee providing a written instrument to the Company notifying the Company of such assignment and agreeing
in writing to be bound by the terms of this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. 
 7.2    Governing Law. This Agreement shall be governed by and construed in accordance with the
internal laws of the State of Washington, without regard to its principles of conflicts of laws. 

7.3    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 7.4    Titles and Subtitles. The titles and subtitles
used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

7.5    Notices. All notices, requests, and other communications given or made pursuant to this Agreement shall be
in writing and shall be deemed effectively given (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so
confirmed, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a nationally recognized
overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses on file with the Company, or to such email
address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 7.5. If notice is given to the Company, which notice shall be sent to the attention of the
Company’s General Counsel, and a copy shall also be sent to DLA Piper LLP (US), 701 Fifth Avenue, Suite 6900, Seattle, WA 98104, Attn: Tyler Hollenbeck. 

  
 24 

 7.6    Amendments and Waivers. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the
Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.14(c). Notwithstanding the foregoing: 

(a)    this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with
respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion; 

(b) The definition of “Major Investor”, this Section 7.6(b) and the rights of Major Investors under
Sections 3, 4 and 5 may not be amended, waived or terminated without the written consent of the Major Investors holding a majority of the Preferred Stock then outstanding, including a majority of the Series E-1 Preferred Stock then outstanding; 
 (c)    any holder of Preferred Stock may
become a party to this Agreement by signing a counterpart signature or joinder without the written consent of any Investor or Key Holder, and Schedule A shall be updated to reflect such additional party to this Agreement; and 

(d)    Sections 5 and 6 may not be amended or terminated without the written consent of the Key Holders.

 Any amendment, termination, or waiver effected in accordance with this Section 7.6 shall be binding on all
parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or
continuing waiver of any such term, condition, or provision. 
 7.7    Severability. In case any one or more of
the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

7.8    Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 

7.9    Prior Agreement; Entire Agreement. The Prior IRA is hereby amended and restated in its entirety by this
Agreement, and as of the date hereof the Prior IRA shall be deemed superseded hereby. This Agreement (including any Schedules hereto) constitutes the full and entire understanding and agreement between the parties with respect to the subject matter
hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

  
 25 

 7.10    Dispute Resolution. The parties (a) hereby
irrevocably and unconditionally submit to the jurisdiction of the state courts of the State of Washington and to the jurisdiction of the United States District Court for the Western District of Washington for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the State of Washington or the United States
District Court for the Western District of Washington, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that
this Agreement or the subject matter hereof may not be enforced in or by such court. Each party hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect of any suit, action or other
proceeding arising out of or based upon this Agreement. 
 7.11    Delays or Omissions. No delay or omission to
exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall
it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Signature Pages Follow.] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	 Adaptive Biotechnologies Corporation

		
	By:	 	/s/ Chad M. Robins
		 	Chad M. Robins
		 	President

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	KEY HOLDERS:
	
	/s/ Chad M. Robins
	Chad M. Robins

  
  

			
	South Dakota Trust Company, Trustee of the Harlan Robins 2017 Trust U/T/A dated December 14, 2017
		
	By:	 	/s/ Frances R. Becker
	Name:	 	Frances R. Becker
	Title:	 	Directed Trustee

  

			
	HSR 2014 Father’s Trust U/T/A dated June 17, 2014
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Trustee

  

			
	HSR 2014 Mother’s Trust U/T/A dated June 17, 2014
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Co-trustee

  

			
		
	By:	 	/s/ Chad Robins
	Name:	 	Chad Robins
	Title:	 	Co-trustee

  

			
	HSR 2017 Trust for Descendants, U/A/D November 10, 2017
		
	By:	 	/s/ Chad Robins
	Name:	 	Chad Robins
	Title:	 	Trustee

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	KEY HOLDERS:
	
	/s/ Harlan S. Robins
	Harlan S. Robins

  

			
	CMR 2014 Father’s Trust U/T/A dated July 2, 2014
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Trustee

  

			
	CMR 2014 Mother’s Trust U/T/A dated July 2, 2014
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Co-trustee

  

			
		
	By:	 	/s/ Harlan Robins
	Name:	 	Harlan Robins
	Title:	 	Co-trustee

  

			
	CMR 2014 Brother’s Trust U/T/A dated July 2, 2014
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Co-trustee

  

			
		
	By:	 	/s/ Harlan Robins
	Name:	 	Harlan Robins
	Title:	 	Co-trustee

  

			
	CMR 2018 BRR Trust, u/a/d October 3, 2018
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Trustee

  

			
	CMR 2018 SRR Trust, u/a/d October 3, 2018
		
	By:	 	/s/ Karen E. Robins
	Name:	 	Karen E. Robins
	Title:	 	Trustee

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	KEY HOLDER:
	
	 VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

By: Viking Global Opportunities Portfolio GP LLC
 Its:
Investment Manager

		
	By:	 	/s/ Matthew Bloom
	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory

  

			
	INVESTORS:
	
	 VIKING GLOBAL EQUITIES II LP

By: Viking Global Performance LLC
 Its: General
Partner

		
	By:	 	/s/ Matthew Bloom
	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory

  

			
	 VIKING GLOBAL EQUITIES MASTER LTD.

By: Viking Global Performance LLC
 Its: General
Partner

		
	By:	 	/s/ Matthew Bloom
	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory

  

			
	 VIKING LONG FUND MASTER LTD. 

By: Viking Long Fund GP LLC
 Its: Investment Manager

		
	By:	 	/s/ Matthew Bloom
	Name:	 	Matthew Bloom
	Title:	 	Authorized Signatory

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 
  

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	MATRIX CAPITAL MANAGEMENT MASTER FUND, LP
		
	By:	 	 /s/ David E. Goel

	Name:	 	 David E. Goel

	Title:	 	 Managing General Partner

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTORS:

	
	 SWEETWATER SECONDARIES FUND II L.P.

		
	By:	 	 Sweetwater Secondaries Fund II GP LLC

	Its:	 	 General Partner

		
	By:	 	 /s/ Brent Granado

	Name:	 	 Brent Granado

	Title:	 	 Managing Partner

	
	SWEETWATER REVELATION, LLC
		
	By:	 	 /s/ Brent Granado

	Name:	 	 Brent Granado

	Title:	 	 Managing Partner

	
	SW SECONDARIES II A LLC 
		
	By:	 	 /s/ Brent Granado

	Name:	 	 Brent Granado

	Title:	 	 Managing Partner

	
	SW SECONDARIES II B LLC 
		
	By:	 	 /s/ Brent Granado

	Name:	 	 Brent Granado

	Title:	 	 Managing Partner

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Seventh Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

							
	INVESTOR (if individual):	 		 	INVESTOR (if entity or trust):
			
	  
	 		 	  

			
	Signature	 		 	Name of Entity or Trust
				
	  
	 		 	By:	 	
                 

	Name (type or print)	 		 	Name:	 	  

				
	  
	 		 	Its:	 	  

				
	Signature of Co-Signer (if any)	 		 		 	
				
	  
	 		 		 	
				
	Name of Co-Signer (type or print)	 		 		 	

  

			
	Address:	 	
                 

		 	  

		 	  

 [SIGNATURE PAGE TO ADAPTIVE BIOTECHNOLOGIES CORPORATION 

SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
667, L.P.

	
Adam Garber Roth IRA

	
Akita Investments, LLC

	
Alexandria Equities, LLC

	
Allen, Charles S.

	
Allen, Charles S. Jr.

	
Allen, Graham C.

	
Allen, James

	
Anderson, James E.

	
Asbury, Thomas

	
Baker Brothers Life Sciences, L.P.

	
Baker, Eric H.

	
Ballenger, John R., M.D. PSP

	
Barbara A. Clark Revocable Trust dated November 14, 2002

	
Barton, Douglas

	
Beck Family Trust U/A/D 08/14/98

	
Beck, Charles A., Jr, M.D.

	
Becton, Dickenson and Company

	
Beebe, Mark

	
Bezwada, Hari P.

	
Bocceri, Frederic R. and Bonita M. Bahre

	
Brennan, Sean P.

	
Brighton, Charles

	
Brunhofer, Brian

	
Bushell, Douglas and Stephanie

	
Candida Abrahamson Revocable Trust, Dated Oct. 12, 2015

	
Carlson Family Trust

	
Carlton, Abigail and Scott Stucky

	
Carlton, Charles and Caroline

	
Casdin Partners Master Fund LP

	
Celgene Corporation

	
Chapin, Sam

	
Chatalas, Bret

	
Chatalas, Marc

	
Chatalas, William B.

	
Christian, Matt

	
Chu, Stanley

	
Clothier, Kirk A.

	
CMR 2014 Brother’s Trust U/T/A dated July 2, 2014

	
CMR 2014 Father’s Trust U/T/A dated July 2, 2014

	
CMR 2014 Mother’s Trust U/T/A dated July 2, 2014

	
Constantino, Matthew

	
Crile, Chet

	
Cummings, Craig

	
Daniel, Steven

	
David W. Miller and Sheila F. Miller Joint Tenants with Rights of Survivorship

	
Decheng Capital China Life Sciences USD Fund I,
L.P.

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
Declaration of Trust of Renee M. Schoenberg dated 2/24/81, as amended

	
Dee, Sutee

	
DeMaio, Craig

	
Demashkeih, Rasha

	
Diamond, Betty

	
Diane Cress Cabelof Trust

	
Dogra, Devinder

	
Dondero, John and Carey

	
Dondero, Kristopher

	
Duea, Brad and Cristi

	
Dyson, Patricia Heakin

	
East Elkhorn Valley, LLC

	
Eiting, Elizabeth

	
Epstein, Robert

	
Equitus Capital LLC

	
Equity Trust Company FBO Elizabeth P Holmes

	
Equity Trust Company, d.b.a. Sterling Trust Custodian FBO William P. Holmes SEP IRA

	
EquityZen Growth Technology Fund LLC – Series 346

	
EquityZen Growth Technology Fund LLC – Series 368

	
Eskenazi, Michael

	
Fang, Lei

	
Farzad Nazem & Noosheen Hashemi Living Trust Dated 7/10/95

	
Fidelity Management Trust Co. Custodian for G. Edward Means Roth IRA

	
Forbes-Eisner Family Trust, UTD Nov. 26, 2001

	
Frank Dominguez, Jr. Grantor Retained Annuity Trust

	
Frank Dominguez, Jr. Revocable Trust

	
Fraser, Katherine E.

	
Frederic R. Bocceri Profit Sharing Plan

	
Garber, Adam

	
Garber, Elise

	
Garber, Joel

	
Garber, Loren

	
Ghafghaichi, Majid

	
Gildor, Ephraim

	
Gingrich, Robert

	
Glascott, Timothy

	
Gorman, Alvin

	
Gottesman, Daniel

	
Greatrex, Peter

	
Guarantee & Trust Co TTEE FBO Allen J. Ginsburg IRA

	
Haddock, Stephen M.

	
Halperin, Errol R.

	
Hardenbol, Paul

	
Hare & Co., LLC

	
Hazeltime LLC

	
Helms, David B.

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
Helmy A. Eltoukhy Helmy A. Eltoukhy Revocable Trust

	
Hernandez, Luis

	
Hielscher, Richard

	
Higgins, Frank M.

	
Holmstrom, John and Barbara, JTROS

	
HSR 2014 Father’s Trust U/T/A dated June 17, 2014

	
HSR 2014 Mother’s Trust U/T/A dated June 17, 2014

	
HSR 2017 Trust For Descendants, U/A/D November 10, 2017

	
Htun, Sai

	
Illumina, Inc.

	
J. Rieger Ltd.

	
Jacobs, Jeffrey H.

	
Jain, Maneesh

	
Jason Krasno Family Trust dated December 7, 2015

	
Johnson, Jeffrey A.

	
Judith A. Ginsburg Trust dated October 4, 2017

	
JWP Properties, LLC

	
Kahn, Matthew and Nichole

	
Karen E. Robins, Trustee of the CMR 2018 SRR Trust, u/a/d October 3, 2018

	
Karen E. Robins, Trustee of the CMR 2018 BRR Trust, u/a/d October 3, 2018

	Karen E. Robins, Trustee of the Lawrence A Robins GST Marital Trust, u/a/d
September 12, 2016
	
Karlin-Neumann, George

	
Katz, Ronald C.

	
Keane, Peter

	
Keehnel, Stellman

	
Keim Family Trust u/a/d August 11, 2016

	
Kelly E. Fitz DYN Trust

	
Kemp, Richard Hans

	
Kessler, Irvin

	
Kingfisher Capital LLC

	
Kirk, Karen

	
Klinger, Mark

	
Koplin, Alfred N.

	
Krasno, Jason

	
Laboratory Corporation of America Holdings

	
Laura Gorman Trust

	
Lawrence A. Robins and David Sanders, Trustees of the Elysian 2012 Trust

	
Leffel, Brent

	
Leon and Rhona Schechter Revocable Trust U/A/D 01/08/97

	
Lora K. Eichner Grantor Retained Annuity Trust

	
Lora K. Eichner Revocable Trust

	
Louise K. Stumph Joint Tenants with Rights of Survivorship

	
Lubert, Jonathan

	
Luebeck, Georg

	
Maas, Catherine W.

	
Magnussen, J. Michael

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
Marnee V. Wirth 2000 Trust

	
Matrix Capital Management Master Fund, LP

	
Mayer, Steven and Jean

	
McQuaid, Howard

	
McQuaid, Michael E.

	
McQuaid, Suzanne

	
McQueen, Carrie

	
Mezistrano, Hoda

	
Millenium Trust Co. LLC Cust FBO Karen E. Robins Traditional IRA

	
Millenium Trust Co. LLC Custodian FBO Lee I. Miller Traditional IRA XXXX5C731

	
Mindy Schechter, Trustee of the Mindy Schechter Living Trust

	
Moe, Christopher S.

	
Naimi, Farzad

	
Namsaraev, Eugeni

	
Nathan J. Howard DYN Trust

	
National Financial Services, LLC CUST FBO G. Edward Means Roth IRA

	
National Financial Services, LLC CUST FBO Mark E. Means

	
National Financial Services, LLC CUST FBO Stephani I. Means Guthrie

	
Nelsen, Robert

	
Nicholas, Frank C., III

	
Nolan, Brett

	
Parker, H. Stewart

	
Patel, Mitaben

	
Pedersen, Brandon S.

	
Peller, Carl

	
Peller, Sherry

	
PENSCO Trust Company LLC Custodian FBO Brent Leffel IRA

	
Pensco Trust Company LLC Custodian FBO Craig R. DeMaio IRA

	
Port, Jesse

	
Pothuraju, Kaliprasad

	
Pure, Bradley N.

	
Pure, Jonathan A.

	
Raymond James & Assoc CSDN FBO James Califf III DVM IRA U/A/D 8/12/14 A/C 41406479

	
RBC Capital Markets, LLC Cust FBO Candace Joy SEP IRA

	
RBC Capital Markets, LLC Cust FBO Erik R. Boe IRA

	
Rekant, Mark S.

	
Revocable Living Trust of Richard Edward Meese

	
Rinella, Barbara

	
RLR Family Partners

	
RM Family Dynasty Trust

	
Robins, Chad M.

	
Robins, Harlan S.

	
Rock Springs Capital Master Fund LP

	
Rosen, Joshua

	
Rosen, Mark T.

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
Rowe, Sarah

	
Rowley, James P., III

	
Saadi, Mayas

	
Schreck, Kevin

	
Schutz, Charles and Bea

	
Senator Global Opportunity Master Fund LP

	
Sickle, David B. and Jill

	
Six Points Capital, LLC

	
South Dakota Trust Company, Trustee of the Harlan Robins 2017 Trust

	
Sparks, Andrew

	
Starnes, Benjamin and Marjorie

	
Steel, John M.

	
Sterner, Edwin B.

	
Sunil Puri Trust Dated August 31, 2004

	
Susan R. Sullivan Declaration of Trust dated 3/25/1991

	
SVB Financial Group

	
SW Secondaries II A LLC

	
SW Secondaries II B LLC

	
Sweetwater Revelation, LLC

	
Sweetwater Secondaries Fund II L.P.

	
Swerland, Scott

	
TD Ameritrade Clearing, Inc. as Custodian FBO Charles E. Schutz Roth IRA

	
The Efrusy Family Trust d/t/d
10-21-2005

	
The Gruye Living Trust dated May 22, 1992

	
The Tenenbaum Family Trust

	
The Weissman 2013 Family Trust

	
Tiger Partners, L.P.

	
Tobias, John

	
Urdea, Mickey

	
Veljovich, Dan and Natalie

	
Viking Global Equities II LP

	
Viking Global Equities Master Ltd.

	
Viking Global Opportunities Illiquid Investments Sub-Master LP

	
Viking Long Fund Master Ltd.

	
Wang, Yingmin

	
Ward, Eric

	
Way Family Limited Partnership

	
Weisman Living Trust dated February 15, 2005, and any amendments thereto

	
Weissman, Craig

	
Weng, Li

	
White Oak Capital LLC

	
Wigoda, Ellen S.

	
Willis, Chris

	
Withycombe, Elizabeth

	
WS Investment Company, LLC (2009A)

	
WS Investment Company, LLC (2009C)

	
WS Investment Company, LLC (2012A)

 SCHEDULE A – INVESTORS 

 

	
	Shareholder
	
WS Investment Company, LLC (2013A)

	
Youssefnia, David and Shauna

	
Zheng, Jianbiao

	
Zoltners, Andris A.

	
Zona, JosephEX-4.2

 Exhibit 4.2 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO PURCHASE STOCK 

Company: ADAPTIVE BIOTECHNOLOGIES CORPORATION 
 Number
of Shares: 35,032 
 Type/Series of Stock: Common Stock 

Warrant Price: $0.33 per share 
 Issue Date: June 5th,
2012 
 Expiration Date: June 5th, 2022 See also Section 5.1(b). 

			
	Credit Facility:	 	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith between Silicon Valley Bank and the Company (the
“Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuablc consideration, SILICON VALLEY BANK (together with any
successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and
non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the
“Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference
is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this Warrant to its parent company, SVB Financial Group. 

SECTION 1. EXERCISE. 

1.1    Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part,
by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set
forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares
being purchased. 
 1.2    Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the
aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which
this Warrant is being exercised. Thereupon, 

  
 1 

 
the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

 

					
		 	X = Y(A-B)/A
			
	    where:	 		  	
			
		 	X =	  	the number of Shares to be issued to the Holder;
			
		 	Y =	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
			
		 	A =	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
			
		 	B =	  	the Warrant Price.

 1.3    Fair Market Value. If the Company’s common stock is then traded or
quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the
Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise to the Company. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. 

1.4    Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the
manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new
warrant of like tenor representing the Shares not so acquired. 
 1.5    Replacement of Warrant. On receipt of
evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount
to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

 1.6    Treatment of Warrant Upon Acquisition of Company. 

(a)    Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or
series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or
entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately

  
 2 

 
prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such
merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b)    Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be
received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise this
Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will
expire immediately prior to the consummation of such Acquisition. 
 (c)    The Company shall provide Holder with
written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition
giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if, immediately
prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date,
then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall
promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date
thereof. 
 (d)    Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the
acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of
the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(e)    As used in this Warrant, “Marketable Securities” means securities meeting all of the
following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is
then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition
were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) Holder would be able to publicly re-sell, within six (6) months following the
closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition. 

  
 3 

 SECTION 2.    ADJUSTMENTS TO THE SHARES AND WARRANT
PRICE. 
 2.1    Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on
the outstanding shares of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total
number and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by
reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are
combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2    Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding
shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be
exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3    Reserved. 

2.4    Reserved. 

2.5    No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of
Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by
multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6    Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of
Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The
Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such
adjustment. 

  
 4 

 SECTION 3.    REPRESENTATIONS AND COVENANTS OF THE
COMPANY. 
 3.1    Representations and Warranties. The Company represents and warrants to, and agrees with,
the Holder as follows: 
 (a)    The initial Warrant Price referenced on the first page of this Warrant is not greater
than the price per share at which shares of the Class were valued in the most recent 409A valuation of Borrower’s stock. 

(b)    All Shares which may be issued upon the exercise of this Warrant shall, upon issuance pursuant to the terms
hereof, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein under applicable federal and state
securities laws or created by the Holder. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and other securities
as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c)    The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material
respects, as of the Issue Date. 
 3.2    Notice of Certain Events. If the Company proposes at any time to: 

(a)    declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in
cash, property, stock, or other securities and whether or not a regular cash dividend; 
 (b)    offer for subscription
or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 (c)    effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the
outstanding shares of the Class; 
 (d)    effect an Acquisition or to liquidate, dissolve or wind up; or 

(e)    effect an IPO; 

then, in connection with each such event, the Company shall give Holder: 

(1)    at least seven (7) Business Days prior written notice of the date on which a record will be
taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters
referred to in (a) and (b) above; 
 (2)    in the case of the matters referred to in (c) and
(d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the
securities or other property deliverable upon the occurrence of such event); and 

  
 5 

 (3)    with respect to the IPO, at least seven
(7) Business Days prior written notice of the date on which the Company proposes to file its registration statement in connection therewith. 

Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give
written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting
requirements. 
 SECTION 4.    REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by
Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the
specific purpose of acquiring this Warrant or the Shares. 
 4.2    Disclosure of Information. Holder is aware of
the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant
and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying
securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business
relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4    Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Act. 
 4.5    The Act. Holder understands that this Warrant and the Shares issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the 

  
 6 

 
Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered
under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6    Market Stand-off Agreement. The Holder agrees that the Shares shall
be subject to the Market Standoff provisions in Section 2.12 of the Company’s Amended and Restated Investors’ Rights Agreement, dated as of May 20, 2011, as amended. 

4.7    No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of
this Warrant. 
 SECTION 5.    MISCELLANEOUS. 

5.1    Term and Automatic Conversion Upon Expiration. 

(a)    Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part
at any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 

(b)    Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market
value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of
such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the
Shares (or such other securities) issued upon such exercise to Holder. 
 5.2    Legends. The Shares (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED JUNE 5TH, 2012, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

5.3    Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this
Warrant may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee 

  
 7 

 
(including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor”
as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4    Transfer Procedure. After receipt by Silicon Valley Bank of the executed Warrant, Silicon Valley Bank will
transfer all of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in Section 4 hereof and agrees to
be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group and any subsequent Holder may
transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant to any transferee, provided, however, in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the
portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided
further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the
IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection
with an Acquisition of the Company by such a direct competitor. 
 5.5    Notices. All notices and other
communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after
being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day
following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in
accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

SVB Financial Group 
 Attn:
Treasury Department 
 3003 Tasman Drive, HC 215 

Santa Clara, CA 95054 

Telephone: (408) 654-7400 

Facsimile: (408) 988-8317 

Email address: derivatives @svb.com 

  
 8 

 Notice to the Company shall be addressed as follows until Holder receives notice of a change
in address: 
 Adaptive Biotechnologies Corporation 

Attn: Chad Robins 
 1551
Eastlake Avenue East, Suite 200 
 Seattle, WA 98102 

Telephone: 
 Facsimile: 

Email: 

5.6    Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally
or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any
amendment thereto. 
 5.9    Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of California, without giving effect to its principles regarding conflicts of law. 

5.10    Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise
affect the meaning of any provision of this Warrant. 
 5.11    Business Days. “Business
Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 
 [Remainder of page left blank
intentionally] 
 [Signature page follows] 

  
 9 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ADAPTIVE BIOTECHNOLOGIES CORPORATION
		
	By:	 	 /s/ Chad M. Robins

	Name:	 	 Chad M. Robins

		 	(Print)
	Title:	 	
	
	“HOLDER”
	
	SILICON VALLEY BANK
		
	By:	 	 /s/ Jayson Davis

	Name:	 	 Jayson Davis

		 	(Print)
	Title:	 	Relationship Manager

 APPENDIX 1 

NOTICE OF EXERCISE 

1.    The undersigned Holder hereby exercises its right purchase
                     shares of the Common Stock of ADAPTIVE BIOTECHNOLOGIES CORPORATION (the “Company”) in accordance with
the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: 
  

	 	☐	 check in the amount of $          payable to order of the Company
enclosed herewith 

  

	 	☐	 Wire transfer of immediately available funds to the Company’s account 

 

	 	☐	 Cashless Exercise pursuant to Section 1.2 of the Warrant 

 

	 	☐	 Other [Describe]
                                         
                                    

2.    Please issue a certificate or certificates representing the Shares in the name specified 

 
  

					
		 	  

        Holder’s Name
	 	
			
		 	  
	 	
			
		 	  
	 	
		 	        (Address)	 	

 3.    By its execution below and for the benefit of the Company, Holder hereby restates
each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

			
	HOLDER:
	
	  

		
	By:	 	
                     
                                         
          

	Name:	 	  

	Title:	 	  

	(Date):	 	  

  
 Appendix 1 

 SCHEDULE 1 

Company Capitalization Table 

See attached 

  
 Schedule 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]